Eyegenex

Founded in 2023 by CEO Dr. Prasad Sunkara and Steve Gormican and based in California, US, Eyegenex operates as a pharmaceutical company developing therapies for glaucoma, non-arteritic anterior ischemic optic neuropathy, and diabetic retinopathy. In September 2026, Eyegenex, Inc. raised venture funding from Newsight Tech Angels.

Eyegenex is a biopharmaceutical company focused on ophthalmic therapeutics for vision-threatening eye diseases. The company is developing novel drug therapies targeting glaucoma, non-arteritic anterior ischemic optic neuropathy (NAION), and diabetic retinopathy (DR) with the goal of preventing blindness and reducing vision loss. Its pipeline includes glaucoma therapies that have demonstrated efficacy in animal studies and are progressing toward clinical development, as well as early-stage diabetic retinopathy treatments. The company's activities include drug discovery, preclinical research, translational ophthalmology research, therapeutic development, and clinical advancement of vision-preserving treatments.

Eyegenex is currently a development-stage biotechnology company, so its near-term revenue is likely derived primarily from venture capital funding, seed financing, grants, research collaborations, and strategic partnerships rather than commercial product sales. The company plans to use the September 2026 funding to accelerate completion of its preclinical work and regulatory engagement toward first-in-human testing.